ORKA
Oruka Therapeutics Inc.
$29.29
+$2.30(+8.52%)
67
Overall
60
Value
75
Tech
--
Quality
Market Cap
$1.33B
Volume
397.35K
52W Range
$5.49 - $29.98
Target Price
$46.90
Company Overview
| Mkt Cap | $1.33B | Price | $29.29 |
| Volume | 397.35K | Change | +8.52% |
| P/E Ratio | -248.9 | Open | $26.90 |
| Revenue | -- | Prev Close | $26.99 |
| Net Income | $-5.3M | 52W Range | $5.49 - $29.98 |
| Div Yield | N/A | Target | $46.90 |
| Overall | 67 | Value | 60 |
| Quality | -- | Technical | 75 |
No chart data available
About Oruka Therapeutics Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Latest News
Oruka Therapeutics Reports Q3 2025 Financial Results
TipRanks Auto-Generated Newsdesk•6 days ago
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG) and Oruka Therapeutics (ORKA)
Brian Anderson•11 days ago
Oruka Therapeutics (ORKA) Gets a Buy from Barclays
TipRanks Auto-Generated Intelligence Newsdesk•11 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ORKA | $29.29 | +8.5% | 397.35K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |